Sanoj Punnen, MD, MAS, presented “Integrated Multi-Modality Diagnostic Evaluation of Prostate Cancer” during the Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 1st, 2020.
How to cite: Punnen, Sanoj. “Integrated Multi-Modality Diagnostic Evaluation of Prostate Cancer.” March 2021. Accessed Dec 2024. https://dev.grandroundsinurology.com/integrated-multi-modality-diagnostic-evaluation-of-prostate-cancer/
Integrated Multi-Modality Diagnostic Evaluation of Prostate Cancer – Summary
Sanoj Punnen, MD, MAS, Associate Professor of Clinical Urology in the University of Miami Health System, explains how multimodal detection options could improve and personalize prostate cancer diagnosis, specifically the combination of MRI and biomarkers. He reviews the pros and cons of each option, noting incidence and mortality rates. To bolster his points, Dr. Punnen summarizes data from the PRECISION trial and the PROMIS trial. He also looks at a 2018 trial studying MRI and 4Kscore® for significant prostate cancer detection and a 2021 study that developed a 4Kscore®/MRI‐based tool to assist clinicians in biopsy decision‐making and counseling of those at risk for prostate cancer. Dr. Punnen concludes by calling for further research, specifically studies comparing biomarkers head-to-head and trials focusing on PET imaging and quantitative imaging.
The Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer brings together key international opinion leaders of every clinical subspecialty involved in patient care. This event is an integral part of the AdMeTech Foundation’s Annual Summit, which was established in 2016 and become seminal in shaping the state of the art and future vision for precision care. The goal of this event is three-fold: 1) Educating the key stakeholders; 2) Supporting a sustained cross-disciplinary dialogue and consensus on the best emerging clinical practices and research priorities; and 3) Expediting clinical adoption of promising novel diagnostics and therapeutics. Dr. Punnen presented this on the first day of the conference. For more educational activities from this virtual event, visit our collection page.
ABOUT THE AUTHOR
Sanoj Punnen, MD, MAS, completed his medical school at Queen’s University and urology residency at the University of Toronto in Canada. He then completed a uro-oncology fellowship and Master’s in Clinical Research at the University of California, San Francisco. He is board-certified in both urology and uro-oncology. His primary research interest is in localized prostate cancer. Specifically, his work has evaluated imaging, molecular, and genomic markers that play a role in prostate cancer diagnosis and prognosis. He is also involved in outcomes and health service research on trends in the incidence and management of prostate cancer.
